retatrutide triple hormone receptor agonist obesity 🚨 JUST RELEASED TODAY!!!! NEW PHASE 3 DATA Today, July 23, 2026, new Phase 3 retatrutide results were released, adding to what is already one of the most interesting drug retatrutide obesity triple hormone receptor

Injectable Formulations Dominate Treatment Delivery in Japan Japan will be an outlier on size, not direction

M.FilipskiK

Alm do tratamento do diabetes, muitos pacientes passaram a utilizar essas terapias com foco na reduo de peso e na melhoria da sade metablica

These fibers work by prolonging the contact time between nutrients and the L-cells in the intestine that secrete GLP-1, while also slowing glucose absorption

According to the FDA prescribing information for Zepbound, in the SURMOUNT-1 trial, cholelithiasis was reported in 2.5% of patients receiving tirzepatide compared to 1.0% of patients on placebo

Similarly, Zhou et al